Open AccessImatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells
Author(s) -
Igishi
Publication year - 2009
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or_00000626
Subject(s) - protein kinase b , imatinib mesylate , stem cell factor , pi3k/akt/mtor pathway , cancer research , autocrine signalling , ly294002 , mapk/erk pathway , imatinib , chemistry , pharmacology , kinase , biology , signal transduction , microbiology and biotechnology , stem cell , progenitor cell , biochemistry , receptor , myeloid leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom